All In Biotech

Drug Trial Radar · NCT04780217

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Intravenously as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

42

Planned (sponsor's estimate)

Start

Aug 10, 2021

Primary completion

Mar 2025

Study completion Aug 2025

Sponsor

Lead sponsor
ImmVira Pharma Co. LtdIndustry
Sponsor type
Industry
First posted
Mar 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors

Conditions

  • Solid Tumor
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • NSCLC
  • Ovarian Cancer
  • Endometrial Cancer

Interventions

  • T3011Biological

    T3011 will be administered through IV drip or pumping.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of escalating doses of single agent IV T3011 Characterize DLTs and identify the MTD and/or the RP2D of single agent IV T3011Time frame: Up to 2 years from first dose of T3011

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Phoenix, Arizona

  • BRCR Medical Center Inc

    Plantation, Florida

  • Prisma Health - Upstate

    Greenville, South Carolina

  • Virginia Cancer Specialists

    Greenville, South Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.